How Retail Investors Reacted To Eli Lilly And Novo Nordisk Share Price Declines After Roche’s Positive Drug Data

Shares of pharma majors Eli Lilly and Novo Nordisk witnessed some selling pressure in Wednesday’s pre-market session after Swiss multinational firm Roche disclosed positive data about its weight loss drug. Although both shares fell nearly 3% in pre-market trading, retail investors have shrugged off the negative impact on Eli Lilly and Novo Nordisk with the sentiment meter for both these stocks trending in the neutral to bullish territory.

Roche said in a statement that after four weeks of treatment, its once-daily oral molecule CT-996, developed for treating both type 2 diabetes and obesity, demonstrated clinically meaningful weight loss of -7.3%. The company said that based on the study data, CT-996 is expected to be used not only as a therapy for achieving glycaemic control and inducing weight loss but also for oral weight maintenance therapy following weight loss induced by injectables.

Following the announcement, shares of Roche Holdings rose over 7% in pre-market trading on Wednesday.

The positive news from the competition failed to invoke much negative sentiment from retail investors for Eli Lilly and Novo Nordisk. The Stocktwits sentiment meter for Eli Lily was trending in bullish territory (73/100) while it was hovering in the neutral zone for Novo Nordisk.

With Roche’s latest disclosure, competition appears to be intensifying in the weight loss drug market. Eli Lilly’s drug Zepbound was approved by the US Food and Drug Administration (USFDA) in November 2023 while Novo Nordic’s Wegovy was approved in the US in March this year.

Regarding stock prices, Eli Lilly is trading at a price-to-earnings ratio of 141, whereas Novo Nordisk shares are trading at a multiple of 48.5x. Meanwhile, Roche Holdings ADR is currently trending at a relatively cheaper multiple of 16x. Still, retail investors appear to be looking past the elevated valuations in hopes that these companies can grow into them over time.